Archived explainer. For the current picture see today's CLBT page.
CELLEBRITE DI LTD A (CLBT) is down -29.61% in the latest session. Our newswire has captured 11 stories on CLBT across 7 sources in the last 36 hours, with AI sentiment reading mixed (avg 43/100).
Cellebrite DI Ltd. (CLBT) fell 29.61% to $10.73 in intraday trading on August 13, 2026, marking one of the largest single-day declines in its recent history. The drop followed a mixed Q2 earnings report that included a cut to annual recurring revenue (ARR) and revenue outlooks, despite a raised adjusted EBITDA target. The stock also opened with a modest gap up but quickly reversed direction as investors reacted to the new leadership and legal developments.
The stock’s sharp decline was driven by a combination of factors. Cellebrite announced the appointment of Shiven Ramji as CEO, signaling a leadership transition amid a challenging earnings report. The company lowered its 2026 ARR and revenue guidance but raised its adjusted EBITDA target. This mixed financial picture raised concerns among investors. Additionally, the firm is under investigation for potential securities law violations by Block & Leviton, which added to the uncertainty. The stock opened at $15.48, a modest 1.5% gap up from the previous close, but quickly fell into a steep decline, hitting a session low of $9.58. The stock closed the session at $10.73, with 32.9 million shares traded, 16.7 times the 3-month average.
The stock has been in a steep bearish trend, down 33.8% over the past eight sessions. Intraday volume surged sharply, reflecting heightened investor activity and concern. Recent insider transactions also signaled caution, with three executives, CMO Gee David Nicholas, Global Chief Revenue Officer Marcus Jewell, and CFO David Barter, selling shares in the past two weeks. Over the last 90 days, insiders have sold a total of $2.6 million worth of stock, with no insider buying recorded. Additionally, unusual options activity included two notable prints, with call options generating $1.3 million in premium, though no put activity was reported.
Cellebrite’s next key event will be the release of its full Q2 earnings transcript, which is already available through Benzinga. Investors should also monitor the company’s ability to stabilize its guidance and address the ongoing securities investigation. Coverage breadth remains high, with 11 stories published in the last 36 hours.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
Cellebrite DI Ltd. experienced a 33% post-earnings drop, but I view this as an overreaction given its robust fundamentals. Click for this CLBT stock update.
Boston, Massachusetts--(Newsfile Corp. - August 13, 2026) - Block Leviton is investigating Cellebrite DI (NASDAQ: CLBT) for potential securities law violations. Investors who have lost money in their...
Cellebrite (CLBT) names Shiven Ramji CEO as Q2 results cut 2026 ARR/revenue outlook but raise EBITDA target; shares drop 28% premarket.
Why is Cellebrite stock plunging today?
Cellebrite names Shiven Ramji as CEO amid a mixed Q2 financial picture: ARR and revenue outlooks are trimmed, but adjusted EBITDA guidance is revised higher. The company's focus on innovation and new product momentum sets the stage for the next growth phase.
More on CLBT: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier CLBT move explainers: 2026-08-13